| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Challenges of artificial intelligence in precision oncology: public-private partnerships including national health agencies as an asset to make it happen
|
Luu, V.P.
|
|
|
35 |
2 |
p. 154-158
|
article
|
| 2 |
Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer
|
Ros, J.
|
|
|
35 |
2 |
p. 240-241
|
article
|
| 3 |
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
|
Tran, H.T.
|
|
|
35 |
2 |
p. 183-189
|
article
|
| 4 |
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Loibl, S.
|
|
|
35 |
2 |
p. 159-182
|
article
|
| 5 |
Editorial Board
|
|
|
|
35 |
2 |
p. iii
|
article
|
| 6 |
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
|
Lewis, K.D.
|
|
|
35 |
2 |
p. 221-228
|
article
|
| 7 |
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer
|
Rolfo, C.
|
|
|
35 |
2 |
p. 147-149
|
article
|
| 8 |
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
|
Necchi, A.
|
|
|
35 |
2 |
p. 200-210
|
article
|
| 9 |
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma☆
|
Lian, B.
|
|
|
35 |
2 |
p. 211-220
|
article
|
| 10 |
Table of Contents
|
|
|
|
35 |
2 |
p. i-ii
|
article
|
| 11 |
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
|
Yan, X.Q.
|
|
|
35 |
2 |
p. 190-199
|
article
|
| 12 |
Unlocking precision oncology with FGFR inhibition in urothelial carcinoma
|
Sonpavde, G.P.
|
|
|
35 |
2 |
p. 150-153
|
article
|
| 13 |
Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer—evaluation in a nationwide Danish cohort
|
Henriksen, T.V.
|
|
|
35 |
2 |
p. 229-239
|
article
|
| 14 |
Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline
|
Cervantes, A.
|
|
|
35 |
2 |
p. 241-243
|
article
|
Journal description